Ra Capital Management, L.P. Infla Rx N.V. Transaction History

Ra Capital Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$3.06 - $51.61 $8.6 Million - $145 Million	-2,810,708 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$31.16 - $48.62 $22.6 Million - $35.3 Million	725,619 Added 34.8%	2,810,708 $106 Million
Q4 2018 Feb 14, 2019	BUY	$23.33 - $36.37 $2.74 Million - $4.26 Million	117,241 Added 5.96%	2,085,089 $75.8 Million
Q3 2018 Nov 14, 2018	BUY	$29.34 - $35.0 $20,538 - $24,500	700 Added 0.04%	1,967,848 $67.5 Million
Q2 2018 Aug 14, 2018	BUY	$27.33 - $41.46 $9.47 Million - $14.4 Million	346,495 Added 21.38%	1,967,148 $63.4 Million
Q1 2018 May 15, 2018	SELL	$20.21 - $32.0 $25.4 Million - $40.2 Million	-1,255,427 Reduced 43.65%	1,620,653 $46.7 Million
Q4 2017 Feb 14, 2018	BUY	$14.55 - $23.99 $41.8 Million - $69 Million	2,876,080	2,876,080 $60.3 Million

12.9M

19.3K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $99M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.